Oxford Textbook of Clinical and Biochemical Disorders of the Skeleton 2 is a definitive reference providing comprehensive coverage of common polygenic and rare monogenic disorders, emphasizing new advances in bone cell biology and human skeletal disease. With an up-to-date account of common and rare metabolic disorders of the skeleton, including their causes, clinical aspects, and treatment, this book offers the reader clarity in the complex field of the molecular biology of the skeleton. Topics covered include bone biology and investigation, osteoporosis, osteomalacia and rickets, parathyroid bone disease, Paget disease, and the effects of malignancy on the skeleton. Newer metabolic bone disorders are also included, along with chapters on osteogenesis imperfecta, skeletal dysplasias, osteopetrosis and osteosclerosis, Marfan syndrome, Ehlers-Danlos syndrome, fibrous dysplasia, and ectopic mineralisation. Essential for postgraduates and clinicians, this accessible and highly illustrated book provides a clear authoritative account of metabolic bone diseases in their widest sense. Bringing together considerable advances in the field, it discusses molecular causes and personal experiences of all disorders, ensuring a comprehensive and didactic reference. Enriched with over 100 new illustrations and revised chapters to reflect a rapidly developing field, this second edition will be indispensable for those who look after patients with metabolic bone disease, including general physicians, rheumatologists, endocrinologists, and orthopaedic surgeons, along with paediatricians and geneticists. This print edition of The Oxford Textbook of Clinical and Biochemical Disorders of the Skeleton comes with a year's access to the online version on Oxford Medicine Online. By activating your unique access code, you can read and annotate the full text online, follow links from the references to primary research materials, and view, enlarge and download all the figures and tables. Oxford Medicine Online is mobile optimized for access when and where you need it.

Although phosphorylation of proteins on tyrosine is relatively rare compared to phosphorylation on serine or threonine residues, the past two decades of research into PTP function have led to a great appreciation of the critical role PTPs have in regulating basic cellular processes. Among these important roles is the regulation of cellular signaling pathways related to metabolism. This volume contains chapters which highlight many aspects of PTP function in the context of metabolism. Given the growing obesity and diabetes epidemics in the United States and throughout the world, the desire to identify possible therapeutic targets for treatment of these diseases is a high priority. In many ways, PTPs may be attractive drug targets since they are amenable to targeting with small molecules; however many challenges abound in making PTP inhibitors.

This book discusses both the beneficial and harmful aspects of NO in biology and medicine, and also introduces the emerging discovery of artemisinin in antitumor, antibacterial infection, anti-inflammation, and antiaging contexts. In 1992 nitric oxide (NO) was voted "Molecule of the Year" by Science magazine, and the discovery of its physiological roles has led to Nobel Prize-winning work in neuroscience, physiology and immunology. The book explains why we should maintain a steady-state NO level that is derived from neuronal or epithelial NO synthase, and avoid the extremely high NO level resulting from inducible NO synthase. The book offers a valuable resource for medical chemists, clinicians, biologists and all those interested in health and disease.

This handbook is an overview of the diagnosis, treatment and long-term management of diabetic retinopathy, within the context of overall long-term diabetes disease management. Diabetes-related eye damage (diabetic retinopathy) is one of the most common complications of diabetes, affecting approximately 30-40% of people with diabetes. The situation is so severe that in countries such as the US and UK, diabetic retinopathy is currently the leading cause of blindness in people age 20 to 74 years old. Fortunately, there are several existing and emerging treatments on the horizon and with adequate control of the underlying diabetes, this condition can be successfully managed.

This book will be the first that focuses on solely on model organisms for lymphoma. It's editors are internationally recognized in the field.

Over the last twenty years, type 2 diabetes skyrocketed to the forefront of global public health concern. In this book, Mari Armstrong-Hough examines the rise and response to the disease in two societies: the United States and Japan. Both societies have faced rising rates of diabetes, but their social and biomedical responses to its ascendance have diverged. To explain the emergence of distinctive strategies to explain and manage diabetes, Armstrong-Hough argues that physicians act on not only increasingly globalized professional standards but also on local knowledge, explanatory models, and cultural toolkits. As a result, strategies for clinical management diverge sharply from one country to another. Armstrong-Hough demonstrates how distinctive practices endure in the midst of intensifying biomedicalization, both on the part of patients and on the part of physicians, and how these differences grow from broader cultural narratives about diabetes in each setting.

Vassopressin, Volume 111, the latest release in the Vitamins and Hormones series, first published in 1943, covers the field of hormone action, vitamin action, X-ray crystal structure, physiology and enzyme mechanisms, with this release focusing on topics relating to hepcidin, bacterial infection, and iron overload, the role of heparan sulfates in hepcidin regulation, hepcidin CDNA and human gene sex hormones, growth factors and hepcidin, HFE gene polymorphisms and hereditary hemochromatosis, hepcidin and il-1beta, hepcidin-ferroportin axis, cardiomyocyte hepcidin, adipocyte iron, leptin and hepcidin, regulators of hepcidin expression, and much more.

Different genetic diagnostic and treatment options are used worldwide to improve routine IVF procedures for the benefit of patients. This handbook updates the new genetic diagnostic technologies that have been translated to the clinic, aiming to improve outcomes in the clinic and result in a healthy baby in the home. Chapters cover the use of genetic technologies in a personalized manner to unravel the possible genetic risks for the couple wishing to conceive, in terms of sperm, the embryo, the endometrium, miscarriage, and finally the fetus. This expanded new edition covers the range of the latest genetic diagnostic technologies being translated into practice internationally to improve routine IVF procedures for the benefit of patients. Bringing together international experts to discuss their work, this text gives a context for the developments in this very fast-moving area of research and offers a comprehensive and rounded appraisal of hot topics.

This book is intended to provide up-to-date and emerging information in the field of diabetes mellitus with a focus on preventive, predictive and personalized medicine.

This book is part of a series dedicated to recent advances on preventive, predictive and personalised medicine (PPPM). It focuses on the theme of "Drug delivery systems: advanced technologies potentially applicable in personalised treatments". The critical topics involving the development and preparation of effective drug delivery systems, such as: polymers available, self-assembly, nanotechnology, pharmaceutical formulations, three dimensional structures, molecular modeling, tailor-made solutions and technological tendencies, are carefully discussed. The understanding of these areas constitutes a paramount route to establish personalised and effective solutions for specific diseases and individuals.

The study of Burkitt's lymphoma is now in its 6 decade beginning with its discovery by Dr. Dennis Burkitt in equatorial Africa in the mid to late 1950's. A large body of information is available which provides a current understanding of the underlying molecular changes that are linked to the initiation and development of Burkitt's lymphoma. This proposed volume will provide a comprehensive view of Burkitt's Lymphoma from the diagnosis to potential animal models for this disease and include a view from physicians who have a up close view of the patients in populations where the disease is rampant. We expect that this will be an excellent resource for Medical students and faculty as well as educated laypersons who have a person interest in the disease.

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

Circadian rhythms are such an innate part of our lives that we rarely pause to speculate why they even exist. Some studies have suggested that the disruption of the circadian system may be causal for obesity and manifestations of Metabolic Syndrome (MetS). Shift-work, sleep-deprivation and bright-light-exposure at night are related to increased adiposity (obesity) and prevalence of MetS. It has been provided evidence of clock genes expression in human adipose tissue and demonstrated its association with different components of the MetS. Moreover, current studies are illustrating the particular role of different clock genes variants and their predicted haplotypes in MetS. The purpose of "Chronobiology and Obesity" is to describe the mechanisms implicated in the interaction between chonodisruption and metabolic-related illnesses, such as obesity and MetS, with different approaches.

This volume features contributions from participants of an ESRF Workshop on "Systems Biology" held in Berkeley, USA, in November 2005. Significant progress has been made in developing technologies that enable systems interrogations at a molecular level. Recent successes and challenges of applying systems level measurements to the different steps of drug discovery and development in the pharmaceutical industry are summarized.

These two volumes are unique in that they take into consideration the enormous progress made in the field over the last few years. Expert knowledge is given by Professor Runnebaum, whose department was appointed WHO Collaboration Center for Research in Human Reproduction. These extensively illustrated books provide detailed information on the function and detection of new hormones and growth factors, on therapy with female sexual hormones, on environmental factors, and on the diagnostic and surgical techniques employed in reproductive medicine. This English edition of a standard German reference has been expanded to include an appendix containing a comprehensive list of pharmaceutical agents used in hormone therapy, including international and trade names and compositions.

Insulin-like growth factor (IGF)-I is a widely expressed growth factor with diverse effects on many tissues throughout development and in adult life. The purpose of this work is to provide detailed and updated information on the role of the growth hormone (GH)-IGF axis in fetal and postnatal development, as well as its physiological functions and implications in pathology.

Until recently, the renin-angiotensin-aldosterone system has been considered a systemic endocrine hormonal system exclusively. It is now known that each component of the renin-angiotensin system is produced, synthesized and indeed, present in many organisms including the heart and vessels. This volume presents the most recent clinical and laboratory experiences of the leading physicians and investigators in the field of the local cardiac renin-angiotensin aldosterone system. Cardiovascular, renal and hypertension oriented physicians, investigators and scientists would find this book of interest. Edward D. Frohlich, M.D., M.A.C.P, F.A.C.C., is the Alton Ochsner Distinguished Scientist at the Ochsner Clinic Foundation in New Orleans, Louisiana. He is also Professor of Medicine and of Physiology at Louisiana State University School of Medicine, New Orleans, and Clinical Professor of Medicine and Adjunct Professor of Pharmacology at Tulane University School of Medicine, New Orleans. He is past Editor-in-Chief of the American Heart Association journal HYPERTENSION. Richard N. Re, M.D., is the Section Head, Hypertension at the Ochsner Clinic Foundation in New Orleans, Louisiana. He is also Ochsner's Scientific Director of Research.

Current molecular understanding of estrogen action has greatly profited from advances in molecular cell biology. These advances, and their implications for clinical use, were discussed by leading researchers from industry and academia during an international symposium held in Berlin, 1-3 March 2006 and are featured in this volume.

This concise drug guide lists 500 substances, such as pharmaceutical drugs, lifestyle drugs, and environmental toxicants, which show documented untoward effects on the male sexual organs and their functions. All substances are listed in user-friendly alphabetical order with a uniform structure throughout the book. Each listing includes evidence-based information with up-to-date references and all studies mentioned are evaluated and categorized according to study and sample types. This unique compendium provides more detailed information on each drug than any other standard pharmacology title.

This is the first comprehensive volume on Dipeptidyl Aminopeptidases that can be marketed to a wide variety of disciplines, as well as to a variety of clinicians. Leading experts in the field contribute to this state-of-the-art view on these enzymes. This book comes at a time when our understanding of their function is growing ever more rapidly and therapeutic options have become imminent.

Clinical Urologic Endocrinology: Principles for Men's Health provides an organized, accessible reference on men's endocrinological health. Over 30 million men in the US alone suffer from erectile dysfunction and over 13 million men in the US suffer from hypogonadism (low testosterone). One out of seven couples also suffer from subfertility of which 50-60% have male factor involvement. More and more men are coming forward to seek treatment for such issues, which in the past were considered taboo and there is a strong need for a book which provides guidance for practitioners who support men in their reproductive and sexual concerns. This book covers in depth the key issues in male reproductive health in one easy-to-use resource. Clinical Urologic Endocrinology: Principles for Men's Health is a valuable reference for urologists, endocrinologists, internal medicine physicians, family medicine physicians, sex therapists, and allied health professionals providing care for men in the areas of sexual health, fertility, and men's endocrinological health.

Ghrelin, the endogenous ligand for the growth hormone secretagogue (GHS) receptor, is critical in the control of food intake and energy balance. The ghrelin receptors are now known to have important physiological properties as modulators of growth hormone release, appetite, glucose homeostasis, metabolism, immune function, neurotransmitter activity, cognitive function and neurodegeneration. Bringing all of this information together in the first comprehensive text on the topic, Ghrelin in Health and Disease provides a state-of-the-art synthesis of the latest work in this area for physicians and physician-scientists. This volume addresses the unique property of ghrelin as a modulator of function. Such a property provides potential utility for safe intervention in a wide variety of disease states. Indeed as we learn more about the basic physiology of ghrelin, the potential for treating new disease targets emerge requiring validation in the clinic. Each chapter in this volume is authored by a leading investigator in the field. The introductory chapter sets the background for the book and provides a superb overview of the relevance of ghrelin to physiology, describing how the discovery of ghrelin has prompted us to completely rethink traditional physiology. The authors conclude their chapters by critically addressing the future translational aspects of ghrelin biology and outlining what key basic research and clinical questions remain to be addressed. An invaluable resource, Ghrelin in Health and Disease distinguishes itself as the first comprehensive title covering all of the molecular and clinical issues relating to ghrelin and advancing our clinical understanding of obesity, growth, and reproductive pathogenesis.

In 1925, J. B. Collip (1925) reported that extracts of parathyroid gland contained an activity that raised calcium levels in the blood of parathyroidectomized animals, and suggested that this was due to a hormone produced in the parathyroid gland. The story of parathyroid hormone discovery was indicative of ever-increasing sophistication in sample preparation and protein isolation techniques. This paper resolved earlier controversies over the function of the parathyroid glands and c- trol of blood calcium. The year 1961 was a banner year for parathyroid research, in which the peptides parathyroid hormone and calcitonin were purified, and in which it was suggested that calcitonin could lower blood calcium (Copp and Cameron 1961). In 1982 it was discovered that in neurons the primary RNA transcript for calcitonin could be alternatively-spliced to give calcitonin gene-reated peptide (CGRP), and shortly thereafter amylin (previously named islet amyloid polyp- tide, IAPP) was identified and shown to have homology to CGRP. Since then a and b CGRP have been delineated and adrenomedullin and intermedin discovered, and this family of homologous peptides has emerged. This family of peptide hormones has a diverse and constantly expanding range of important physiologic functions, including regulation of blood calcium, vascular tension, feeding behavior and pain recognition.

The obesity epidemic has generated immense interest in recent years due to the wide-ranging and significant adverse health and economic consequences that surround the problem. Much attention has been focused on behaviors that lead to obesity, in particular to over consumption of energy-dense food and to sedentary lifestyle. However, obesity is an extremely complex condition with poorly defined pathogenesis. Thanks to greatly enhanced research in the area, the discovery of pathways in the brain and peripheral organs that mediate energy homeostasis has provided a framework for understanding the biological basis of obesity. Metabolic Basis of Obesity adds an important new dimension to the growing literature on obesity by offering a comprehensive review of specifically how metabolic imbalance culminates in obesity. Developed by a team of expert authors, this important title discusses the principles of energy balance, genetics of body weight regulation, hormones and adipokines, and metabolic pathways in the brain, liver, muscle and fat, to name just several of the areas covered. The book also examines the connection between obesity and diabetes, cardiovascular disease and other complications. Current and future diagnostic and treatment strategies are also reviewed. Comprehensive and timely, Metabolic Basis of Obesity is an essential reference for understanding the burgeoning problem of obesity.

In the mid 1990s, Drs. Gerald Reaven identified a constellation of clinical findings, known variously as the metabolic syndrome, syndrome X, insulin resistance s- drome or insulin resistance-related disorders, that are associated with an increased risk of heart disease and diabetes. Interest in this topic grew rapidly, culminating in the publication by this series of the book, Insulin Resistance and the Metabolic Syndrome X, edited by Drs. Reaven and Laws in 1999. Since the original publication of that now classic volume, the world's population has continued to become more obese and sedentary and the prevalence of disorders related to insulin resistance has continued to increase throughout the developed and developing world. Of great concern in the last decade is the extension of these deleterious lifestyle patterns to the pediatric population, leading to both obesity and the appearance of insulin resistance-related disorders in youth as well as adults. Today, about one in three children and adolescents in the United States is overweight or obese, and this prevalence approaches one in two among adolescents in certain minority groups. In addition, components of this cardiovascular risk constellation are now being recognized in young adults, adolescents, and even children. Youth are increasingly developing type 2 diabetes, fatty liver disease, hypertriglyceridemia, hypertension, polycystic ovarian syndrome, sleep apnea, orthopedic and psychiatric complications, as well as other complications of obesity and insulin resistance.